Associations between Serum Kallistatin Levels and Markers of Glucose Homeostasis, Inflammation, and Lipoprotein Metabolism in Patients with Type 2 Diabetes and Nondiabetic Obesity.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • Subject Terms:
      Diabetes Mellitus, Type 2*/blood ; Diabetes Mellitus, Type 2*/metabolism ; Diabetes Mellitus, Type 2*/complications ; Serpins*/blood ; Obesity*/blood ; Obesity*/metabolism ; Biomarkers*/blood ; Inflammation*/blood; Humans ; Male ; Female ; Middle Aged ; Blood Glucose/metabolism ; Lipoproteins/blood ; Homeostasis ; Adult ; Glycated Hemoglobin/metabolism ; Glycated Hemoglobin/analysis ; Case-Control Studies ; Aged ; C-Reactive Protein/metabolism
    • Abstract:
      Kallistatin is an endogenous serine proteinase inhibitor with various functions, including antioxidative, anti-inflammatory, and anti-atherosclerotic properties. To date, associations between kallistatin and lipoprotein subfractions are poorly investigated. In this study, we enrolled 62 obese patients with type 2 diabetes (T2D), 106 nondiabetic obese (NDO) subjects matched in gender, age, and body mass index, as well as 49 gender- and age-matched healthy, normal-weight controls. Serum kallistatin levels were measured with ELISA, and lipoprotein subfractions were analyzed using Lipoprint ® (Quantimetrix Corp., Redondo Beach, CA, USA) gel electrophoresis. Kallistatin concentrations were significantly higher in T2D patients compared to NDO and control groups. We found significant positive correlations between very-low-density lipoprotein (VLDL), small high-density lipoprotein (HDL) subfractions, glucose, hemoglobin A 1c (HbA 1c ), betatrophin, and kallistatin, while negative correlations were detected between mean low-density lipoprotein (LDL) size, large and intermediate HDL subfractions, and kallistatin in the whole study population. The best predictor of kallistatin was HbA 1c in T2D patients, high-sensitivity C-reactive protein (hsCRP) and betatrophin in NDO patients, and hsCRP in controls. Our results indicate that kallistatin expression might be induced by persistent hyperglycemia in T2D, while in nondiabetic subjects, its production might be associated with systemic inflammation. The correlation of kallistatin with lipid subfractions may suggest its putative role in atherogenesis.
    • References:
      Hypertension. 2010 Aug;56(2):260-7. (PMID: 20566960)
      Pract Lab Med. 2021 Jul 18;26:e00248. (PMID: 34368411)
      N Engl J Med. 2008 Nov 20;359(21):2195-207. (PMID: 18997196)
      Int J Endocrinol. 2014;2014:323407. (PMID: 24963292)
      Metabolism. 2013 May;62(5):642-6. (PMID: 23190873)
      Immunology. 2014 Jun;142(2):216-26. (PMID: 24467264)
      J Biol Chem. 1993 Nov 15;268(32):24498-505. (PMID: 8227002)
      Acta Biochim Biophys Sin (Shanghai). 2020 Jun 20;52(6):583-589. (PMID: 32393963)
      Int J Mol Sci. 2023 Feb 18;24(4):. (PMID: 36835525)
      Int J Mol Sci. 2014 Dec 18;15(12):23640-57. (PMID: 25530616)
      Transplant Proc. 2018 Sep;50(7):2105-2109. (PMID: 30177118)
      Int J Mol Sci. 2023 Nov 19;24(22):. (PMID: 38003693)
      Hum Gene Ther. 2006 Dec;17(12):1201-13. (PMID: 17081080)
      Vasc Med. 2015 Dec;20(6):509-17. (PMID: 26091968)
      Endocr Res. 2017 May;42(2):163-168. (PMID: 28406338)
      J Lipids. 2021 Apr 26;2021:5585521. (PMID: 33996157)
      Metabolism. 2019 Mar;92:71-81. (PMID: 30447223)
      J Invest Dermatol. 2014 Jun;134(6):1725-1734. (PMID: 24463424)
      Am J Physiol Heart Circ Physiol. 2010 Nov;299(5):H1419-27. (PMID: 20729399)
      J Am Heart Assoc. 2014 Sep 18;3(5):e001194. (PMID: 25237049)
      Arch Toxicol. 2023 Jun;97(6):1529-1545. (PMID: 37084080)
      Exp Clin Transplant. 2024 Jan;22(Suppl 1):243-246. (PMID: 38385405)
      J Cell Biochem. 2014 Mar;115(3):575-84. (PMID: 24129914)
      Clin Endocrinol (Oxf). 2014 Sep;81(3):370-7. (PMID: 24303851)
      Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38. (PMID: 34964875)
      Minerva Endocrinol. 2018 Sep;43(3):236-245. (PMID: 28294594)
      FASEB J. 2020 Jun;34(6):8428-8441. (PMID: 32352602)
      Genomics. 1994 Sep 15;23(2):370-8. (PMID: 7835886)
      Sci Rep. 2015 Jun 16;5:10949. (PMID: 26077345)
      BMC Cardiovasc Disord. 2023 Nov 1;23(1):533. (PMID: 37914996)
      J Clin Endocrinol Metab. 2014 Oct;99(10):E2004-9. (PMID: 25050901)
      J Clin Med. 2021 Dec 10;10(24):. (PMID: 34945088)
      Metabolism. 2018 Oct;87:123-135. (PMID: 29679615)
    • Grant Information:
      K142273 National Research, Development and Innovation Office - NKFIH; TKP2021-EGA-18 Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund; 11003 Eötvös Loránd Research Network
    • Contributed Indexing:
      Keywords: betatrophin; diabetes; kallistatin; lipid subfractions; obesity; triglyceride
    • Accession Number:
      0 (kallistatin)
      0 (Serpins)
      0 (Biomarkers)
      0 (Blood Glucose)
      0 (Lipoproteins)
      0 (Glycated Hemoglobin)
      9007-41-4 (C-Reactive Protein)
    • Publication Date:
      Date Created: 20240619 Date Completed: 20240619 Latest Revision: 20240620
    • Publication Date:
      20240620
    • Accession Number:
      PMC11173135
    • Accession Number:
      10.3390/ijms25116264
    • Accession Number:
      38892451